James Brenton

James D. Brenton is a medical oncologist specialising in gynaecological cancer, a senior group leader at the Cancer Research UK (CRUK) Cambridge Institute, and Professor of Ovarian Cancer Medicine at the University of Cambridge. He leads the Functional Genomics of Ovarian Cancer Laboratory and is joint lead for the CRUK Cambridge Centre Women's Cancer programme and the Mark Foundation Institute for Integrated Cancer Medicine. He was elected a Fellow of the European Academy of Cancer Sciences in 2015.

His research focuses on understanding the extreme genomic complexity of ovarian cancer and identifying blood and tissue genomic biomarkers to predict therapy response. His group was the first to show that mutations in the TP53 gene are ubiquitous in high-grade serous ovarian carcinoma, and to discover copy number aberration signatures of mutational processes. He has used these discoveries to develop personalised circulating tumour DNA assays and genomic biomarkers for use in clinical trials.